EP4006153 - ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 31.05.2024 Database last updated on 11.11.2024 | |
Former | Grant of patent is intended Status updated on 24.01.2024 | ||
Former | Examination is in progress Status updated on 27.01.2023 | ||
Former | Request for examination was made Status updated on 02.12.2022 | ||
Former | The application has been published Status updated on 29.04.2022 | Most recent event Tooltip | 24.07.2024 | Change - representative | Applicant(s) | For all designated states Curocell Inc. 11, Gukjegwahak 16-ro Yuseong-gu Daejeon, 34002 / KR | For all designated states Korea Advanced Institute of Science and Technology 291 Daehak-ro Guseong-dong, Yuseong-gu Daejeon 34141 / KR | [2024/27] |
Former [2022/22] | For all designated states Curocell Inc. 3rd floor, KHE Building 48 Yuseong-daero 1184 beon-gil Yuseong-gu Daejeon 34050 / KR | ||
For all designated states Korea Advanced Institute of Science and Technology 291 Daehak-ro Guseong-dong, Yuseong-gu Daejeon 34141 / KR | Inventor(s) | 01 /
KIM, Chan Hyuk 34141 Daejeon / KR | 02 /
LEE, Young-Ho 34189 Daejeon / KR | 03 /
LEE, Yujean 34070 Daejeon / KR | 04 /
LEE, HyeongJi 34168 Daejeon / KR | 05 /
LEE, Sang Hoon 34116 Daejeon / KR | [2022/22] | Representative(s) | Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street London E1 8QS / GB | [N/P] |
Former [2024/27] | Carridge, Andrew Edward Reddie & Grose LLP The White Chapel Building 10 Whitechapel High Street London E1 8QS / GB | ||
Former [2022/22] | Jones Day Rechtsanwälte, Attorneys-at-Law, Patentanwälte Prinzregentenstrasse 11 80538 München / DE | Application number, filing date | 21207719.2 | 10.01.2019 | [2022/22] | Priority number, date | KR20180004238 | 12.01.2018 Original published format: KR 20180004238 | [2022/22] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP4006153 | Date: | 01.06.2022 | Language: | EN | [2022/22] | Type: | B1 Patent specification | No.: | EP4006153 | Date: | 03.07.2024 | Language: | EN | [2024/27] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 03.05.2022 | Classification | IPC: | C12N15/113 | [2022/22] | CPC: |
C12N15/113 (EP,KR);
C12N15/63 (KR);
A61K2239/31 (EP,KR,US);
A61K2239/48 (EP,KR,US);
A61K31/7088 (US);
A61K38/177 (EP,US);
A61K38/1774 (US);
A61K39/3955 (US);
A61K39/4611 (EP,KR,US);
A61K39/4631 (EP,KR,US);
A61K39/4636 (EP,KR,US);
A61K39/464412 (EP,KR,US);
A61P35/00 (EP,US);
C07K14/4702 (US);
C07K14/7051 (EP,KR,US);
C07K14/70521 (US);
C07K14/70578 (US);
C07K16/2803 (EP,US);
C07K16/2809 (EP);
C07K16/2818 (EP);
C07K16/30 (KR);
C12N15/1075 (EP);
C12N15/1138 (EP,US);
C12N5/0636 (EP,KR,US);
C12N5/0637 (EP,KR,US);
C12N5/0646 (EP,KR,US);
A61K2039/505 (US);
C07K2317/31 (EP);
C07K2317/53 (US);
C07K2317/622 (EP,KR,US);
C07K2317/70 (EP);
C07K2317/73 (EP);
C07K2319/00 (EP);
C07K2319/02 (US);
C07K2319/03 (EP,KR,US);
C07K2319/30 (US);
C07K2319/33 (EP,US);
C07K2319/715 (US);
C12N2310/122 (US);
C12N2310/14 (EP,US);
C12N2310/531 (US);
C12N2320/31 (EP,US);
C12N2320/32 (US);
C12N2330/51 (EP);
C12N2510/00 (KR,US);
C12Q2525/301 (KR)
(-)
| C-Set: |
C12N15/1075, C12Q2525/207 (EP);
C12N2310/531, C12N2310/14 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/01] |
Former [2022/22] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | VERBESSERTE IMMUNZELLEN UNTER VERWENDUNG VON DUALER SHRNA UND ZUSAMMENSETZUNG DAMIT | [2022/22] | English: | ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME | [2022/22] | French: | CELLULES IMMUNITAIRES AMÉLIORÉES UTILISANT UN ARNSH DOUBLE ET COMPOSITION LES COMPRENANT | [2022/22] | Examination procedure | 01.12.2022 | Amendment by applicant (claims and/or description) | 01.12.2022 | Examination requested [2023/01] | 01.12.2022 | Date on which the examining division has become responsible | 26.01.2023 | Despatch of a communication from the examining division (Time limit: M06) | 04.08.2023 | Reply to a communication from the examining division | 22.08.2023 | Despatch of a communication from the examining division (Time limit: M04) | 19.12.2023 | Reply to a communication from the examining division | 25.01.2024 | Communication of intention to grant the patent | 24.05.2024 | Fee for grant paid | 24.05.2024 | Fee for publishing/printing paid | 24.05.2024 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP19738866.3 / EP3737765 | Fees paid | Renewal fee | 11.11.2021 | Renewal fee patent year 03 | 11.11.2021 | Renewal fee patent year 04 | 11.01.2023 | Renewal fee patent year 05 | 04.01.2024 | Renewal fee patent year 06 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]US2007036773 (COOPER LAURENCE [US], et al); | [A]WO2017040945 (MEMORIAL SLOAN KETTERING CANCER CENTER [US]); | [X]US2017356010 (FROST GREGORY IAN [US], et al); | [XP]WO2018049471 (BENITEC BIOPHARMA LTD [AU]); | [XP]WO2018156886 (UNIV NEBRASKA [US]) | Examination | WO2015142675 | WO2016126608 | US2016311917 | WO2017158019 | by applicant | US4690915 | US5858358 | US5883223 | US6352694 | US6534055 | US6692964 | US6797514 | US6867041 | US6887466 | US6905680 | US6905681 | US6905874 | US2006121005 | US7067318 | US7144575 | US7172869 | US7175843 | US7232566 | WO2015090230 | US9169483 | US9181544 | WO2015179525 | WO2016069282 | KR20180004238 |